The biologics contract development market is expanding rapidly, fueled by rising demand for outsourcing services, cost efficiency, and advanced biologics production technologies. Valued at USD 9.07 billion in 2025, the market is set to reach USD 23.01 billion by 2034 at a CAGR of 10.90%, with strong growth across oncology, immunological disorders, and cell line development services
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biologics Contract Development Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biologics Contract Development Market, by Source
8.1.1 Microbial
8.1.1.1. Market Revenue and Forecast
8.1.2. Mammalian
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Biologics Contract Development Market, by Product Service
9.1.1. Cell Line Development
9.1.1.1. Market Revenue and Forecast
9.1.2. Process Development
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Biologics Contract Development Market, by Indication
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Immunological disorders
10.1.2.1. Market Revenue and Forecast
10.1.3. Cardiovascular disorders
10.1.3.1. Market Revenue and Forecast
10.1.4. Hematological disorders
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Source
11.1.2. Market Revenue and Forecast, by Product Service
11.1.3. Market Revenue and Forecast, by Indication
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Source
11.1.4.2. Market Revenue and Forecast, by Product Service
11.1.4.3. Market Revenue and Forecast, by Indication
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Source
11.1.5.2. Market Revenue and Forecast, by Product Service
11.1.5.3. Market Revenue and Forecast, by Indication
11.2. Europe
11.2.1. Market Revenue and Forecast, by Source
11.2.2. Market Revenue and Forecast, by Product Service
11.2.3. Market Revenue and Forecast, by Indication
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Source
11.2.4.2. Market Revenue and Forecast, by Product Service
11.2.4.3. Market Revenue and Forecast, by Indication
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Source
11.2.5.2. Market Revenue and Forecast, by Product Service
11.2.5.3. Market Revenue and Forecast, by Indication
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Source
11.2.6.2. Market Revenue and Forecast, by Product Service
11.2.6.3. Market Revenue and Forecast, by Indication
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Source
11.2.7.2. Market Revenue and Forecast, by Product Service
11.2.7.3. Market Revenue and Forecast, by Indication
11.3. APAC
11.3.1. Market Revenue and Forecast, by Source
11.3.2. Market Revenue and Forecast, by Product Service
11.3.3. Market Revenue and Forecast, by Indication
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Source
11.3.4.2. Market Revenue and Forecast, by Product Service
11.3.4.3. Market Revenue and Forecast, by Indication
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Source
11.3.5.2. Market Revenue and Forecast, by Product Service
11.3.5.3. Market Revenue and Forecast, by Indication
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Source
11.3.6.2. Market Revenue and Forecast, by Product Service
11.3.6.3. Market Revenue and Forecast, by Indication
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Source
11.3.7.2. Market Revenue and Forecast, by Product Service
11.3.7.3. Market Revenue and Forecast, by Indication
11.4. MEA
11.4.1. Market Revenue and Forecast, by Source
11.4.2. Market Revenue and Forecast, by Product Service
11.4.3. Market Revenue and Forecast, by Indication
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Source
11.4.4.2. Market Revenue and Forecast, by Product Service
11.4.4.3. Market Revenue and Forecast, by Indication
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Source
11.4.5.2. Market Revenue and Forecast, by Product Service
11.4.5.3. Market Revenue and Forecast, by Indication
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Source
11.4.6.2. Market Revenue and Forecast, by Product Service
11.4.6.3. Market Revenue and Forecast, by Indication
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Source
11.4.7.2. Market Revenue and Forecast, by Product Service
11.4.7.3. Market Revenue and Forecast, by Indication
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Source
11.5.2. Market Revenue and Forecast, by Product Service
11.5.3. Market Revenue and Forecast, by Indication
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Source
11.5.4.2. Market Revenue and Forecast, by Product Service
11.5.4.3. Market Revenue and Forecast, by Indication
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Source
11.5.5.2. Market Revenue and Forecast, by Product Service
11.5.5.3. Market Revenue and Forecast, by Indication
12.1. Abzena Ltd
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bionova Scientific, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioXcellence
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Curia Global, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Fujifilm Diosynth Biotechnologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Genscript
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. KBI Biopharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. STC Biologics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description